Zurochka, A.; Dobrinina, M.; Zurochka, V.; Hu, D.; Solovyev, A.; Ryabova, L.; Kritsky, I.; Ibragimov, R.; Sarapultsev, A.
Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study. Vaccines 2021, 9, 627.
https://doi.org/10.3390/vaccines9060627
AMA Style
Zurochka A, Dobrinina M, Zurochka V, Hu D, Solovyev A, Ryabova L, Kritsky I, Ibragimov R, Sarapultsev A.
Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study. Vaccines. 2021; 9(6):627.
https://doi.org/10.3390/vaccines9060627
Chicago/Turabian Style
Zurochka, Alexandr, Maria Dobrinina, Vladimir Zurochka, Desheng Hu, Alexandr Solovyev, Liana Ryabova, Igor Kritsky, Roman Ibragimov, and Alexey Sarapultsev.
2021. "Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study" Vaccines 9, no. 6: 627.
https://doi.org/10.3390/vaccines9060627
APA Style
Zurochka, A., Dobrinina, M., Zurochka, V., Hu, D., Solovyev, A., Ryabova, L., Kritsky, I., Ibragimov, R., & Sarapultsev, A.
(2021). Seroprevalence of SARS-CoV-2 Antibodies in Symptomatic Individuals Is Higher than in Persons Who Are at Increased Risk Exposure: The Results of the Single-Center, Prospective, Cross-Sectional Study. Vaccines, 9(6), 627.
https://doi.org/10.3390/vaccines9060627
